anti-Myosin Binding Protein C, Cardiac (MYBPC3) Antikörper

MYBPC3 encodes the cardiac isoform of myosin-binding protein C. Zusätzlich bieten wir Ihnen MYBPC3 Kits (16) und MYBPC3 Proteine (5) und viele weitere Produktgruppen zu diesem Protein an.

Alle Antikörper anzeigen Gen GeneID UniProt
MYBPC3 17868  
MYBPC3 295929 P56741
MYBPC3 4607 Q14896
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top anti-MYBPC3 Antikörper auf antikoerper-online.de

Showing 10 out of 87 products:

Katalog Nr. Reaktivität Wirt Konjugat Applikation Bilder Menge Lieferzeit Preis Details
Rind (Kuh) Kaninchen Unkonjugiert WB Host:  Rabbit  Target Name:  MYBPC3  Sample Type:  MCF7 Whole cell lysates  Antibody Dilution:  1.0ug/ml 100 μL 2 bis 3 Tage
$289.00
Details
Human Kaninchen Unkonjugiert ELISA, IHC, WB Western blot analysis of MYBPC3 using anti-MYBPC3 antibody .  Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours. The sample well of each  Lane was loaded with 50ug of sample under reducing conditions.   Lane 1: rat heart tissue lysates, Lane 2: mouse heart tissue lysates.  After Electrophoresis, proteins were transferred to a Nitrocellulose membrane at 150mA for 50-90 minutes. Blocked the membrane with 5% Non-fat Milk/ TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-MYBPC3 antigen affinity purified polyclonal antibody (Catalog # ) at 0.5 µg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:10000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for MYBPC3 at approximately 160KD. The expected band size for MYBPC3 is at 147KD. IHC analysis of MYBPC3 using anti-MYBPC3 antibody . MYBPC3 was detected in paraffin-embedded section of rat heart tissue. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1µg/ml rabbit anti-MYBPC3 Antibody  overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen. 100 μg 4 bis 6 Tage
$280.00
Details
Human Kaninchen Unkonjugiert EIA, IHC (p), WB Immunohistochemistry analysis in human heart tissue (Formalin-fixed, Paraffin-embedded) using MYBPC3 Antibody (N-term), followed by peroxidase conjugated secondary antibody and DAB staining. This data demonstrates the use of this antibody for IHC. Clinical relevance has not been evaluated. Western blot analysis in mouse heart tissue lysates (35ug/lane) using MYBPC3 Antibody (N-term). This demonstrates this antibody detected the MYBPC3 protein (arrow). 0.4 mL 6 bis 8 Tage
$484.00
Details
Human Kaninchen Unkonjugiert IHC, WB Immunohistochemical analysis of MYBPC3 staining in human heart formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the Western blot analysis of MYBPC3 expression in mouse heart (A), rat heart (B) whole cell lysates. 200 μL 13 bis 14 Tage
$487.50
Details
Human Kaninchen Unkonjugiert IHC, ELISA Immunohistochemistry analysis of paraffin-embedded human heart tissue, using MYBPC3 Antibody. The picture on the right is treated with the synthesized peptide. 100 μg 2 bis 3 Tage
$302.50
Details
Human Kaninchen Unkonjugiert ELISA, IHC, IHC (p) 100 μL 11 bis 14 Tage
$493.17
Details
Human Kaninchen Unkonjugiert ELISA, WB Western blot analysis of MYBPC3 using Jurkat whole cell lysates 100 μL 11 bis 12 Tage
$390.77
Details
Human Kaninchen Unkonjugiert IHC (p), WB Antibody staining MYBPC3 in human skeletal muscle tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Antibody staining MYBPC3 in human heart tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). 400 μL 2 bis 3 Tage
$515.63
Details
Human Kaninchen Unkonjugiert ELISA, IHC   100 μL Verfügbar
$363.46
Details
Human Kaninchen Unkonjugiert IHC, WB   100 μL 2 bis 3 Tage
$295.00
Details

Am meisten referenzierte anti-MYBPC3 Antikörper

  1. Human Polyclonal MYBPC3 Primary Antibody für ELISA, IHC - ABIN5693035 : Qian, Gong, Yang, Chen, Chen, Xu, Wu, Tang, Gao, Zeng: Diastolic dysfunction in spontaneous type 2 diabetes rhesus monkeys: a study using echocardiography and magnetic resonance imaging. in BMC cardiovascular disorders 2015 (PubMed)

Weitere Antikörper gegen MYBPC3 Interaktionspartner

Cow (Bovine) Myosin Binding Protein C, Cardiac (MYBPC3) Interaktionspartner

  1. N terminus of cMyBP-C interacts with F-actin through multiple distinct binding sites and that binding at one or more sites is reduced by phosphorylation

Mouse (Murine) Myosin Binding Protein C, Cardiac (MYBPC3) Interaktionspartner

  1. Combined in vitro and in silico data suggest that the Y235S mutation directly disrupts internal and surface properties of the C1 domain of cMyBPC, which potentially alters its ligand-binding interactions. These molecular changes may underlie the mechanism for hypercontractile cross-bridge behavior, which ultimately results in the development of cardiac hypertrophy and in vivo cardiac dysfunction.

  2. We conclude that cMyBP-C binding to actin contributes to sustained thin filament activation at the end of systole and during isovolumetric relaxation. These results provide the first functional evidence that cMyBP-C interactions with actin influence cardiac function in vivo.

  3. The hyperplastic to hypertrophic transition phase of heart development was altered in mice lacking MYBPC3 and this was the critical period for subsequent development of cardiomyopathy. Specifically, MYBPC3-null hearts developed evidence of increased cardiomyocyte endoreplication, which was accompanied by enhanced expression of cell cycle stimulatory cyclins and increased phosphorylation of retinoblastoma protein.

  4. The ablation of MYBPC3 and muscle-LIM protein protected the mice from developing the dilated cardiomyopathy phenotype.

  5. these findings suggest the possibility that Fhod3 contributes to the pathogenesis of cMyBP-C-related cardiomyopathy and that Fhod3 is critically involved in cMyBP-C-mediated regulation of cardiac function via direct interaction.

  6. Diltiazem recently showed promising beneficial effects in pre-clinical HCM, particularly in patients carrying MYBPC3 mutations.

  7. the widely observed phenomenon of slowed force development in the presence of cMyBP-C may actually be a manifestation of cooperative binding of this protein to the thin filament.

  8. autophagy is impaired in Mybpc3-targeted knockin mice

  9. cMyBP-C lacking the S2 binding site is incorporated normally into the sarcomere, although systolic function is compromised.

  10. these data indicate a robust proinflammatory response in DCM hearts, likely in response to cellular damage triggered by MYBPC3 mutation and resultant contractile dysfunction.

  11. We provide evidence that haploinsufficiency and poison polypeptide hypotheses are disease mechanisms and that EHTs can be used as a platform to evaluate the direct impact of (newly identified) MYBPC3 gene variants.

  12. These results support the proposal that cMyBP-C stabilises the thick filament and that the loss of cMyBP-C results in an untethering of myosin heads.

  13. Crypts are a normal part of cardiac development but, along with the mitral valve and trabeculae, their developmental trajectory is altered by the presence of HCM truncating Mybpc3 gene mutation

  14. that in the homozygous hypertrophic cardiomyopathy mouse model, beta-AR stimulation leads to preferential PKA phosphorylation of phospholamban over cardiac troponin I, resulting in an impaired inotropic and lusitropic response

  15. Phosphorylation of MYBPC3 contributes to the genesis of ventricular wall geometry, linking myofilament biology with multiscale cardiac mechanics and myoarchitecture.

  16. The cMyBP-C hypertrophic cardiomyopathy variant L348P enhances thin filament activation through an increased shift in tropomyosin position.

  17. The contributions of cardiac myosin binding protein C and troponin I phosphorylation to beta-adrenergic enhancement of in vivo cardiac function

  18. calcium levels at the peak of contraction would allow cMyBP-C to remain a potent contractile modulator, regardless of cMyBP-C's phosphorylation state

  19. Phosphorylation reduced the level of molecular disorder and the distribution of C0C2 intramolecular distances became more compact, with probes flanking either the motif between C1 and C2 or the Pro/Ala-rich linker (PAL) between C0 and C1

  20. the phosphorylation pattern of sMyBP-C is differentially regulated following reversible (i.e. fatigue) and non-reversible (i.e. age and disease) (patho)physiological stressors.

Human Myosin Binding Protein C, Cardiac (MYBPC3) Interaktionspartner

  1. Study of intraventricular septum samples from hypertrophic cardiomyopathy patients and a panel of human MYBPC3 mutations expressed in neonatal rat ventricular cardiomyocytes revealed suggest that wild type and mutant MYBPC3 proteins are clients for HSC70, and that the HSC70 chaperone system plays a major role in regulating MYBPC3 protein turnover.

  2. This is the first study to demonstrate intercellular variation of myofilament cMyBP-C protein expression within the myocardium from HCM patients with heterozygous MYBPC3 mutations.

  3. MYBPC3Delta25bp/D389V is associated with hyperdynamic features, which are an early finding in hypertrophic cardiomyopathy, in South Asian descendants in the United States.

  4. A discrete Bayes network interprets fulfilled and predicted 4ddps with conditional probabilities for phenotype and pathogenicity given mutation location and residue substitution thus relating the neural network implicit model to explicit features of the motor and mybpc3 sequence and structural domains.

  5. A total of 98 of 155 gene-tested patients carried a non-benign variant. The primary affected gene was MYH7 in 35% (MYH7+) and MYBPC3 in 49% (MYBPC3+). MYH7+ patients had earlier disease onset and higher risk of major adverse cardiac events (MACE)

  6. A zebrafish model proved to be a useful tool to characterize the pathogenicity of human c-MYBPC3 missense mutations identified in patients with cardiac disease.

  7. the longer N-terminal fragment (C0C3) must possess the requisite domains needed to bind specifically to the thin filament in order for the cMyBP-C N terminus to modulate cardiac contractility.

  8. Compound heterozygous mutations in MYBPC3 were identified as a cause of severe familial hypertrophic cardiomyopathy.

  9. The authors describe a pathogenic variant in MYBPC3 that shares with most truncating pathogenic variants in this gene 3 characteristics of : a late onset; a relatively benign clinical course in the young; and a high age-dependent penetrance.

  10. Report age-at-death variations among MYBPC3 protein-truncating variant carriers in adult males.

  11. Serum cMyC concentration is associated with myocardial hypertrophy, fibrosis and an increased risk of mortality in aortic stenosis.

  12. A missense mutation in cardiac myosin-binding protein C linked to hypertrophic cardiomyopathy decreases stability of the fibronectin type III domain and results in substantially reduced mutant protein expression dissonant to transcript abundance.

  13. Conflicting interpretations of pathogenicity have been reported for the Pro873His MYBPC3 variant described here. Our patient, presenting with two copies of the variant and devoid of a normal allele, progressed to end-stage heart failure, which supports the notion of a deleterious effect of this variant in the homozygous form.

  14. Of the 52 hypertrophic cardiomyopathy patients 11 (21.2%) had MYBPC3 variants.

  15. MYBPC3 does not seem to play a role in anthracycline induced cardiotoxicity.

  16. Mutation in MYBPC3 was identified as Restrictive Cardiomyopathy - causing mutation.

  17. pathogenic gene mutations in LMNA and MYBPC3 alter RNA splicing and may have a role in heart disease

  18. MYBPC3 mutation carriers had a high frequency of ventricular arrhythmia and syncope. An absence of family history of sudden death (SD) and past history of syncope are useful prognostic factors in patients with hypertrophic cardiomyopathy. MYH7 and MYBPC3 mutations did not significantly influence prognosis compared to non-carriers. The patients with the MYBPC3 mutation should be closely followed for the possibility of SD.

  19. Replacement Fibrosis was most abundantly present in the hearts with a MYBPC3 mutation that first presented with a Hypertrophic Cardiomyopathy.

  20. Mutations in the gene MYBPC3 coding for cardiac myosin-binding protein-C (cMyBP-C), a multi-domain protein, are the most common cause of hypertrophic cardiomyopathy ..This molecular insight suggests that key HCM-causing mutations might significantly modify the native affinity required for the assembly of the domains in cMyBP-C, which is essential for normal cardiac function.

Rabbit Myosin Binding Protein C, Cardiac (MYBPC3) Interaktionspartner

  1. small es, CyrillicMyBP-C modulates interaction of myosin with actin

MYBPC3 Antigen-Profil

Protein Überblick

MYBPC3 encodes the cardiac isoform of myosin-binding protein C. Myosin-binding protein C is a myosin-associated protein found in the cross-bridge-bearing zone (C region) of A bands in striated muscle. MYBPC3, the cardiac isoform, is expressed exclussively in heart muscle. Regulatory phosphorylation of the cardiac isoform in vivo by cAMP-dependent protein kinase (PKA) upon adrenergic stimulation may be linked to modulation of cardiac contraction. Mutations in MYBPC3 are one cause of familial hypertrophic cardiomyopathy.

Genbezeichner und Symbole assoziert mit MYBPC3

  • myosin binding protein C, cardiac S homeolog (mybpc3.S) Antikörper
  • myosin binding protein C, cardiac (MYBPC3) Antikörper
  • myosin binding protein C, cardiac (mybpc3) Antikörper
  • myosin binding protein C, cardiac (Mybpc3) Antikörper
  • CMH4 Antikörper
  • FHC Antikörper
  • hm:zehn0716 Antikörper
  • im:6900815 Antikörper
  • MGC114614 Antikörper
  • MYBP-C Antikörper
  • zgc:152717 Antikörper
  • zgc:158442 Antikörper

Bezeichner auf Proteinebene für MYBPC3

myosin binding protein C, cardiac , cardiac myosin-binding protein C , protein C, cardiac , myosin-binding protein C, cardiac-type , cardiac myosin binding protein C , myosin-binding protein C, cardiac-type-like , C-protein, cardiac muscle isoform , cardiac C-protein , cardiac MyBP-C

GENE ID SPEZIES
398261 Xenopus laevis
451168 Pan troglodytes
483624 Canis lupus familiaris
556489 Danio rerio
767614 Bos taurus
100105196 Felis catus
100127177 Xenopus (Silurana) tropicalis
100220915 Taeniopygia guttata
100452875 Pongo abelii
17868 Mus musculus
295929 Rattus norvegicus
4607 Homo sapiens
396013 Gallus gallus
100512088 Sus scrofa
100346773 Oryctolagus cuniculus
Ausgewählte Anbieter für anti-MYBPC3 (MYBPC3) Antikörper
Haben Sie etwas anderes gesucht?